Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

touchFEATURE

Oncogenic mutations in the RAS gene can drive cancer initiation and progression

Open Nav

Animated video

Useful Tips

Learning objectives for this activity are available in the Activity Overview.

Activity Overview

Overview

The RAS family of proteins, which includes the primary members KRAS, NRAS, and HRAS, play a crucial role in the regulation of cell proliferation and survival in normal cells. These proteins function as tightly regulated molecular switches that cycle between the inactive GDP-bound [RAS(OFF)] and active GTP-bound [RAS(ON)] states. This careful regulation maintains a tight balance between RAS in its OFF and ON states.

Oncogenic mutations in the RAS gene can drive cancer initiation and progression, thereby disrupting this balance and resulting in a shift to excessive RAS(ON) signaling in tumor cells. Inhibiting RAS(ON) function can disrupt the activation of signaling pathways and impede tumor growth. However, treatment options for RAS-driven cancers are limited, with currently approved targeted therapies available for a subset of patients with KRAS G12C mutation.

Additional treatment options are needed for patients with G12C mutations, as well as new therapies targeting other oncogenic RAS mutations beyond G12C.

Learning Objectives

After watching this activity, participants should be better able to:

Understand the role of RAS proteins and the associated downstream signaling pathways in the regulation of cell proliferation and survival
Describe how mutations in the RAS gene, which occur in a substantial number of cancers, can drive cancer initiation and progression
Be aware of the limited treatment options available and unmet needs in the management of RAS-driven cancers

touchFEATURE

This content is intended for healthcare professionals only.

Continue

Decline

This activity is sponsored by Revolution Medicines, Inc.

Revolution Medicines provided financial support and content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

This activity is sponsored by Revolution Medicines, Inc.

Revolution Medicines provided financial support and content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Unapproved products or unapproved uses of approved products may be discussed; these situations may reflect the approval status in one or more jurisdictions. TMC has advised the sponsor to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.

The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.

RVMD-GLO-00073 V1.0 12/2025
Date of preparation: December 2025

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

Learning Activities

Congress Highlights

Journals

Specialities

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

Oncogenic mutations in the RAS gene can drive cancer initiation and progression